Since 2020, when 68Ga-PSMA-11 was approved by the FDA (78), prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer employing 68Ga-labelled complexes is increasingly being adopted in routine clinical treatment worldwide. This evidence concerns the gene FOLH1 and prostate cancer.